Based on the Haleon plc stock forecast from 2 analysts, the average analyst target price for Haleon plc is USD 9.98 over the next 12 months. Haleon plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Haleon plc is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Haleon plc’s stock price was USD 9.39. Haleon plc’s stock price has changed by -2.29% over the past week, -6.29% over the past month and +14.37% over the last year.
No recent analyst target price found for Haleon plc
No recent average analyst rating found for Haleon plc
Company Overview Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom. Read Less
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such ...Read More
Frequently Asked Questions About Haleon plc (HLN) Stock
Based on ratings from 2 analysts Haleon plc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 3 buy, sell and hold ratings.
HLN stock's dividend yield is 1.62%.
Our analysis grades HLN stock's dividend yield at C. This means that HLN stock's dividend yield is above 75% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this HLN may be a average dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for HLN is USD 9.98 over the next 12 months. The maximum analyst target price is USD 10.95 while the minimum anlayst target price is USD 9.
HLN stock's Price/Earning ratio is 28.62.
Our analysis grades HLN stock's Price / Earning ratio at D+. This means that HLN stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this HLN may be fairly valued for its sector
The last closing price of HLN's stock was USD 9.39.
The most recent market capitalization for HLN is USD 43.99B.
Based on targets from 2 analysts, the average taret price for HLN is projected at USD 9.98 over the next 12 months.
This means that HLN's stock price may go up by +6.32% over the next 12 months.
We can't find any ETFs which contains Haleon plc's stock.
As per our most recent records Haleon plc has 25,408 Employees.
Haleon plc's registered address is The Heights, Weybridge, United Kingdom, KT13 0NY.
You can get more information about it from Haleon plc's website at https://www.haleon.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Haleon plc (HLN) Stock
Based on ratings from 2 analysts Haleon plc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 3 buy, sell and hold ratings.
HLN stock's dividend yield is 1.62%.
Our analysis grades HLN stock's dividend yield at C. This means that HLN stock's dividend yield is above 75% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this HLN may be a average dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for HLN is USD 9.98 over the next 12 months. The maximum analyst target price is USD 10.95 while the minimum anlayst target price is USD 9.
HLN stock's Price/Earning ratio is 28.62.
Our analysis grades HLN stock's Price / Earning ratio at D+. This means that HLN stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this HLN may be fairly valued for its sector
The last closing price of HLN's stock was USD 9.39.
The most recent market capitalization for HLN is USD 43.99B.
Based on targets from 2 analysts, the average taret price for HLN is projected at USD 9.98 over the next 12 months.
This means that HLN's stock price may go up by +6.32% over the next 12 months.
We can't find any ETFs which contains Haleon plc's stock.
As per our most recent records Haleon plc has 25,408 Employees.
Haleon plc's registered address is The Heights, Weybridge, United Kingdom, KT13 0NY.
You can get more information about it from Haleon plc's website at https://www.haleon.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HLN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
